Please Wait...

NTX-I // N-Terminal Crosslinked Telopeptide of Type I Collagen

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

In bone, type I collagen constitute 90% of the organic matrix. Markers of bone resorption in serum or urine can be used to assess changes in bone resorption in various bone diseases or under treatment (Naylor and Eastell, 2012). Cross linked amino-terminal collagen (NTx-I) are peptides derived from the degradation of collagen I. Measurement of these peptides in urine or serum provide information about the bone resorption rate. The specific assay for NTx peptides have been developed in the nineties and urine values have been found to correlate with HPLC measurements of urinary hydroxyproline or pyridinoline in patients with Paget's disease (Hanson et al., 1992). Different studies have since shown the pertinence of NTx measurement for assessing bone resorption rate in other diseases (Bettica et al., 2002; Clemens et al., 1997; Garnero et al., 1996).

Bioclinica Lab employs a manual sandwich immunoassay for measurement in urine (associated with creatinine values) or in serum.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Bioclinica Delivers Individual Case Safety Report (ICSR) Processing w Quality & Consistency While Crossing One Mil… https://t.co/77NOME2Dj7
bioclinica (21 hours ago)
Who made the BioSpace list of 11 most innovative life sciences companies in the world? Ck it out here via @biospace… https://t.co/f9vtRpsbMW
bioclinica (Yesterday)
BREAKING: With a passion for Drug Safety, we’re delighted to share @bioclinica #pharmacovigilance crossed 1M ICSR c… https://t.co/PAdROjo7tE
bioclinica (Yesterday)
RT @isciencebox: Draft and Final FDA Guidances Detail Development of New Drugs for Neurological Disorders @RAPSorg https://t.co/cAewLypUY7
bioclinica (2 days ago)
RT @RAPSorg: Final @US_FDA Rule Requires Medical Device Trials Outside US to Conform to GCP | #Regulatory Focus https://t.co/jgwaqxfiXl #FD…
bioclinica (2 days ago)
Congrats @bioclinica on @Clin_Info_News Best Practices Award 4 "Transformational Med. Imaging in #ClinicalTrials. '… https://t.co/NxauNywq23
bioclinica (6 days ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen